Literature DB >> 14742210

Differential gene expression in auristatin PHE-treated Cryptococcus neoformans.

Tanja Woyke1, Michael E Berens, Dominique B Hoelzinger, George R Pettit, Günther Winkelmann, Robin K Pettit.   

Abstract

The antifungal pentapeptide auristatin PHE was recently shown to interfere with microtubule dynamics and nuclear and cellular division in the opportunistic pathogen Cryptococcus neoformans. To gain a broader understanding of the cellular response of C. neoformans to auristatin PHE, mRNA differential display (DD) and reverse transcriptase PCR (RT-PCR) were applied. Examination of approximately 60% of the cell transcriptome from cells treated with 1.5 times the MIC (7.89 micro M) of auristatin PHE for 90 min revealed 29 transcript expression differences between control and drug-treated populations. Differential expression of seven of the transcripts was confirmed by RT-PCR, as was drug-dependent modulation of an additional seven transcripts by RT-PCR only. Among genes found to be differentially expressed were those encoding proteins involved in transport, cell cycle regulation, signal transduction, cell stress, DNA repair, nucleotide metabolism, and capsule production. For example, RHO1 and an open reading frame (ORF) encoding a protein with 91% similarity to the Schizophyllum commune 14-3-3 protein, both involved in cell cycle regulation, were down-regulated, as was the gene encoding the multidrug efflux pump Afr1p. An ORF encoding a protein with 57% identity to the heat shock protein HSP104 in Pleurotus sajor-caju was up-regulated. Also, three transcripts of unknown function were responsive to auristatin PHE, which may eventually contribute to the elucidation of the function of their gene products. Further study of these differentially expressed genes and expression of their corresponding proteins are warranted to evaluate how they may be involved in the mechanism of action of auristatin PHE. This information may also contribute to an explanation of the selectivity of auristatin PHE for C. neoformans. This is the first report of drug action using DD in C. neoformans.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14742210      PMCID: PMC321525          DOI: 10.1128/AAC.48.2.561-567.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  59 in total

Review 1.  Yeast 14-3-3 proteins.

Authors:  M J van Hemert; G P van Heusden; H Y Steensma
Journal:  Yeast       Date:  2001-07       Impact factor: 3.239

2.  Genomic profiling of the response of Candida albicans to itraconazole treatment using a DNA microarray.

Authors:  M D De Backer; T Ilyina; X J Ma; S Vandoninck; W H Luyten; H Vanden Bossche
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

3.  Transcriptional analyses of antifungal drug resistance in Candida albicans.

Authors:  C N Lyons; T C White
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

4.  The G-protein beta subunit GPB1 is required for mating and haploid fruiting in Cryptococcus neoformans.

Authors:  P Wang; J R Perfect; J Heitman
Journal:  Mol Cell Biol       Date:  2000-01       Impact factor: 4.272

5.  Encapsulation and melanin formation as indicators of virulence in Cryptococcus neoformans.

Authors:  K J Kwon-Chung; J C Rhodes
Journal:  Infect Immun       Date:  1986-01       Impact factor: 3.441

6.  Isolation of dolastatin 10 from the marine cyanobacterium Symploca species VP642 and total stereochemistry and biological evaluation of its analogue symplostatin 1.

Authors:  H Luesch; R E Moore; V J Paul; S L Mooberry; T H Corbett
Journal:  J Nat Prod       Date:  2001-07       Impact factor: 4.050

7.  Gene expression profiling of exposure to TZT-1027, a novel microtubule-interfering agent, in non-small cell lung cancer PC-14 cells and astrocytes.

Authors:  T Natsume; T Nakamura; Y Koh; M Kobayashi; N Saijo; K Nishio
Journal:  Invest New Drugs       Date:  2001       Impact factor: 3.850

8.  Properties of various Rho1 mutant alleles of Cryptococcus neoformans.

Authors:  Y C Chang; L A Penoyer
Journal:  J Bacteriol       Date:  2000-09       Impact factor: 3.490

Review 9.  The Cryptococcus neoformans genome sequencing project.

Authors:  J Heitman; A Casadevall; J K Lodge; J R Perfect
Journal:  Mycopathologia       Date:  1999       Impact factor: 2.574

10.  Cyclic AMP-dependent protein kinase controls virulence of the fungal pathogen Cryptococcus neoformans.

Authors:  C A D'Souza; J A Alspaugh; C Yue; T Harashima; G M Cox; J R Perfect; J Heitman
Journal:  Mol Cell Biol       Date:  2001-05       Impact factor: 4.272

View more
  3 in total

1.  Antineoplastic agents. 590. X-ray crystal structure of dolastatin 16 and syntheses of the dolamethylleuine and dolaphenvaline units.

Authors:  George R Pettit; Thomas H Smith; Jun-Ping Xu; Delbert L Herald; Erik J Flahive; Collin R Anderson; Paul E Belcher; John C Knight
Journal:  J Nat Prod       Date:  2011-05-03       Impact factor: 4.050

2.  Antineoplastic agents. 592. Highly effective cancer cell growth inhibitory structural modifications of dolastatin 10.

Authors:  George R Pettit; Fiona Hogan; Steven Toms
Journal:  J Nat Prod       Date:  2011-05-02       Impact factor: 4.050

3.  Extracellular vesicles produced by Cryptococcus neoformans contain protein components associated with virulence.

Authors:  Marcio L Rodrigues; Ernesto S Nakayasu; Debora L Oliveira; Leonardo Nimrichter; Joshua D Nosanchuk; Igor C Almeida; Arturo Casadevall
Journal:  Eukaryot Cell       Date:  2007-11-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.